Your browser doesn't support javascript.
loading
Efficacy of long-term lanreotide treatment in patients with acromegaly.
Toledano, Yoel; Rot, Liat; Greenman, Yona; Orlovsky, Sophia; Pauker, Yulia; Olchovsky, David; Eliash, Achia; Bardicef, Orit; Makhoul, Ofa; Tsvetov, Gloria; Gershinsky, Michal; Cohen-Ouaqnine, Odile; Ness-Abramof, Rosane; Adnan, Zaina; Ilany, Jacob; Guttmann, Hadassah; Sapir, Mazal; Benbassat, Carlos; Shimon, Ilan.
Afiliación
  • Toledano Y; Unit of Endocrinology & Diabetes, Hillel Yaffe Medical Center, Hadera, Israel.
Pituitary ; 12(4): 285-93, 2009.
Article en En | MEDLINE | ID: mdl-19266287
We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 +/- 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 +/- 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 +/- 26.3 and 579 +/- 177 mug/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 +/- 238 to 276 +/- 147 mug/l (P < 0.001), and mean GH levels, from 5.2 +/- 6.4 to 3.2 +/- 3.0 mug/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos Cíclicos / Acromegalia / Somatostatina / Antineoplásicos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Pituitary Asunto de la revista: ENDOCRINOLOGIA Año: 2009 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos Cíclicos / Acromegalia / Somatostatina / Antineoplásicos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Pituitary Asunto de la revista: ENDOCRINOLOGIA Año: 2009 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos